TCIM
ADVM

TIAA CREF Investment Management’s Adverum Biotechnologies ADVM Stock Holding History

TIAA CREF Investment Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$565K Buy
10,786
+47
+0.4% +$1.9K ﹤0.01% 2549
2018
Q4 		$338K Sell
10,739
-132
-1% -$5.37K ﹤0.01% 2731
2018
Q3 		$658K Sell
10,871
-1,224
-10% -$68.7K ﹤0.01% 2611
2018
Q2 		$641K Buy
+12,095
New +$727K ﹤0.01% 2667
2017
Q2 		– Sell
-7,353
Closed -$199K – 3134
2017
Q1 		$199K Sell
7,353
-214
-3% -$6.09K ﹤0.01% 2994
2016
Q4 		$219K Sell
7,567
-1,755
-19% -$57.4K ﹤0.01% 3030
2016
Q3 		$383 Sell
9,322
-4,876
-34% -$185K ﹤0.01% 2945
2016
Q2 		$449K Buy
14,198
+3,212
+29% +$145K ﹤0.01% 2907
2016
Q1 		$568K Hold
10,986
– – ﹤0.01% 2750
2015
Q4 		$1.05M Hold
10,986
– – ﹤0.01% 2548
2015
Q3 		$905K Buy
10,986
+2,936
+36% +$375K ﹤0.01% 2619
2015
Q2 		$1.31M Buy
8,050
+5,412
+205% +$1.83M ﹤0.01% 2555
2015
Q1 		$1.07M Buy
2,638
+344
+15% +$145K ﹤0.01% 2585
2014
Q4 		$1.24M Buy
2,294
+227
+11% +$87.5K ﹤0.01% 2536
2014
Q3 		$707K Buy
+2,067
New +$615K ﹤0.01% 2825

Other funds holding ADVM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

TIAA CREF Investment Management's ADVM Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Adverum Biotechnologies (ADVM) stake by 0.44% in Q1 2019, buying an estimated $1.9K and bringing the position to 10,786 shares worth $565K. The position accounts for ﹤0.01% of the portfolio, ranked #2549.

TIAA CREF Investment Management first reported a position in ADVM in Q3 2014 and has held it in 15 quarters since. The position peaked at $1.31M in Q2 2015. 83 funds tracked by Wall St. Rank hold ADVM as of Q1 2019.

  • TIAA CREF Investment Management held 10,786 shares of Adverum Biotechnologies worth $565K as of Q1 2019.
  • TIAA CREF Investment Management bought 47 Adverum Biotechnologies shares in Q1 2019, an estimated $1.9K.
  • Adverum Biotechnologies made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2549 holding.
  • TIAA CREF Investment Management first reported a position in Adverum Biotechnologies in Q3 2014 and has held it in 15 quarters since.
  • TIAA CREF Investment Management's Adverum Biotechnologies position peaked at $1.31M in Q2 2015.
  • 83 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.